Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Akebia Therapeutics
AKBA
Akebia Therapeutics
Regulatory Pressures Will Erode Dialysis Growth While Value Will Emerge
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.00
48.5% undervalued
intrinsic discount
25 Aug
US$3.09
1Y
103.3%
7D
1.6%
Loading
1Y
103.3%
7D
1.6%
Author's Valuation
US$6.0
48.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.0
48.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-391m
447m
2014
2017
2020
2023
2025
2026
2028
Revenue US$447.3m
Earnings US$72.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
18.04%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.04%
Calculation
US$72.69m
Earnings '28
x
48.15x
PE Ratio '28
=
US$3.50b
Market Cap '28
US$3.50b
Market Cap '28
/
475.86m
No. shares '28
=
US$7.35
Share Price '28
US$7.35
Share Price '28
Discounted to 2025 @ 7.02% p.a.
=
US$6.00
Fair Value '25
